CRISPR technology has revolutionized biology, from editing genomes to turning genes on or off with precision. Among these tools, CRISPR-based transcriptional activation (CRISPRa) has attracted major interest. Instead of cutting DNA, CRISPRa switches on specific genes, offering potential applications in research, drug discovery, and even therapies.
But a new study from Northwestern University and collaborators raises an important red flag: many commonly used CRISPRa systems are toxic to cells.
Why CRISPRa matters
Traditional gene overexpression relies on inserting extra copies of DNA, which can be messy and imprecise. CRISPRa instead activates a gene directly at its natural location, allowing scientists to study complex processes more faithfully and at scale. It can also target non-coding RNAs and regulatory regions, expanding what can be studied or controlled.
The problem: toxic activators
The research, published in Nature Communications, shows that popular CRISPRa systems, especially the SAM system, which combines dCas9 with strong activation domains like p65 and HSF1, cause serious problems:
-
Low virus titers during delivery, making experiments difficult to perform.
-
Cell death shortly after transduction, even before the targeted gene is activated.
-
No safe expression window: attempts to fine-tune the system with inducible promoters still led to toxicity.
Cells that did survive often reduced expression of the toxic components, meaning results could be skewed by hidden selection pressures. In practice, this means experiments and genetic screens using CRISPRa might be confounded by artifacts.
What’s going on inside cells?
The team found that cells expressing these strong activators experienced:
-
Cell cycle arrest (cells stuck in G1, unable to divide).
-
Apoptosis (programmed cell death).
-
Suppression of key survival genes, including MYC, IRF4, and MCL1, likely because the artificial activators competed with natural transcription factors for limited cofactors.
This “cofactor squelching” disrupts normal transcriptional programs, especially in cancer models that rely heavily on master regulators.
Are there safer alternatives?
Not all CRISPRa activators were equally harmful. Weaker systems such as VP64 or newer designs like eN3x9 showed fewer toxic effects while still activating genes. A recently engineered p300Core mutant also appeared less damaging.
This suggests the next generation of CRISPRa tools could be designed to balance potency with safety.
Why it matters
CRISPRa has been used in large-scale genetic screens and holds promise for therapeutics. But if activator toxicity is not properly accounted for, results may be misleading or, worse, unsafe in clinical settings. The study highlights the importance of rigorous testing before deploying CRISPRa systems in sensitive contexts.
Cosmael ThinkLab commentary
This work is a reminder that biotechnology’s elegance often hides complexity. Tools like CRISPRa are exciting precisely because they offer powerful shortcuts in biology, but shortcuts can come at a cost.
For researchers, the study underscores the need to carefully validate CRISPRa results, considering toxicity as a hidden variable. For biotech innovators, it signals an opportunity: to engineer safer, smarter activators that maintain precision without compromising cell viability.
CRISPRa is far from dead—it’s evolving. The question now is how fast the field can move toward safer, next-generation systems that deliver on its promise.
Source: Liang, Z., Maddineni, A., Ortega, J.A., Magdongon, C.B., Jambardi, S., Roy, S., Tycko, J., Patil, A., Manzano, M., Bartom, E.T., & Gottwein, E. (2025). Cytotoxicity of activator expression in CRISPR-based transcriptional activation systems. Nature Communications